Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Spyre Therapeutics and keeping the price target at $95.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Debanjana Chatterjee has given his Buy rating due to a combination of factors tied to strengthening external validation for Spyre Therapeutics’ inflammatory bowel disease strategy. Recent proof-of-concept data from AbbVie’s α4β7/IL-23p19 combination in difficult-to-treat Crohn’s patients showed substantially better endoscopic remission than either monotherapy, supporting the broader view that dual-pathway combinations can deliver markedly superior outcomes in this setting.
Chatterjee argues that Spyre’s purpose-built co-formulations are well positioned to capitalize on this trend, offering potential advantages in convenience, pricing, safety and target engagement versus emerging rivals. The expected quarterly or longer dosing schedule could be more attractive than competitors’ monthly regimens, and if Spyre can price its combinations near the cost of a single biologic, adoption earlier in the treatment algorithm becomes more likely. With external combo data aligning with Spyre’s thesis and its development timeline tracking closely with large peers, the unchanged $95 price target and Buy rating are maintained.
In another report released today, LifeSci Capital also assigned a Buy rating to the stock with a $105.00 price target.